AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

by Barry101 | Aug 30, 2022 | Press Release, Uncategorized

Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA, Fla., Aug. 30, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM)...

AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

by Barry101 | Aug 18, 2022 | Press Release, Uncategorized

Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug. 18, 2022 — AIM...

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

by Barry101 | Aug 15, 2022 | Press Release, Uncategorized

OCALA, Fla. – AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases,...

AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

by Barry101 | Aug 15, 2022 | Press Release, Uncategorized

– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones –...

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

by Barry101 | Jul 28, 2022 | Press Release, Uncategorized

Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditionsOCALA, Fla., July 28, 2022 — AIM...

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

by Barry101 | Jul 20, 2022 | Press Release, Uncategorized

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the...